Wells Fargo analyst Eva Fortea Verdejo initiated coverage of Immunocore (IMCR) with an Overweight rating and $60 price target The firm believes Kimmtrak “provides a good floor value” for the stock and indication expansion opportunities could offer upside over the next 12 months. There is room for further penetration, especially in the community setting, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMCR:
- Immunocore’s Innovative Approach: A New Hope for PRAME-Positive Cancer Treatment
- Immunocore’s Phase 3 Melanoma Study: A Potential Game Changer?
- Immunocore’s Promising Melanoma Study: A Potential Game-Changer
- Immunocore’s Brenetafusp: A Promising Study in PRAME-Positive Cancers
- Immunocore’s Innovative Cancer Study: A Potential Game-Changer for Investors